TLC-2716
TLC-2716 is an experimental drug and LXR inverse agonist that reduced triglycerides and remnant cholesterol in a clinical trial.
Snapshot
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
TLC-2716 is an experimental drug and LXR inverse agonist that reduced triglycerides and remnant cholesterol in a clinical trial.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1345710814 under CC BY-SA 4.0; modifications have been made.